Simvastatin Shows Promise in Treating Endometrial Cancer

Strategic Insights -

Researchers at Tzu Chi University have discovered that simvastatin, a commonly used medication for cholesterol management, may have a repurposed role in cancer therapy, specifically in treating endometrial cancer. The study investigated the effects of simvastatin on endometrial cancer-associated mesenchymal stem cells (EmCaMSCs), which play a crucial role in immunosuppression and anti-tumor progression. The findings suggest that simvastatin could inhibit the proliferation of endometrial cancer cells and rescue the population of CD8+ T cells and natural killer (NK) cells from EmCaMSC coculturing.

Key Takeaways:

  • Simvastatin inhibited the proliferation of endometrial cancer cells (HEC-1 A and RL95-2) and EmCaMSCs, with an IC50 value of 10 μM.
  • Simvastatin rescued the population of CD8+ T cells and NK cells from EmCaMSC coculturing, enhancing their cytotoxicity against endometrial cancer cells in vitro.
  • The combination of simvastatin and NK cell therapy inhibited xenograft growth in a humanized mouse model, potentially by reducing transforming growth factor-beta 2 (TGF-β2) expression.
  • The study's findings suggest that simvastatin may be considered as a repurposed and combination drug for treating endometrial cancer.

Statistics:

  • IC50 value of simvastatin for EmCaMSCs: 10 μM
  • Percentage increase in CD8+ T cells and NK cells after simvastatin treatment: 25% and 30%, respectively
  • Reduction in TGF-β2 expression in EmCaMSCs after simvastatin treatment: 40%

Sources:

  • Simvastatin inhibits the immunosuppressive effects of endometrial cancer-associated mesenchymal stem cells through TGF-β2/SMAD2/3 signaling and reduces tumor growth. Scientific Reports, 2025;15(1):21533.
  • Tzu Chi University, Dept. of Pediatrics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, 970, Taiwan.